Urine cytology and commercially available urine-based markers for monitoring of bladder urothelial carcinoma

Jose A. Karam, Yair Lotan, Shahrokh F. Shariat

Research output: Contribution to journalArticlepeer-review

Abstract

Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology requires an experienced cytopathologist. It has high specificity, but low sensitivity for low-grade bladder tumors. Recently, multiple non-invasive urine-based bladder cancer tests have been developed. Many markers have already been approved by the Food and Drug Administration (FDA) for bladder cancer surveillance, but only one marker is approved for detection of bladder cancer in high risk patients (NMP22 BladderChek).

Original languageEnglish (US)
Pages (from-to)48-52
Number of pages5
JournalLaboratory medicine
Volume38
Issue number1
DOIs
StatePublished - 2007

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Urine cytology and commercially available urine-based markers for monitoring of bladder urothelial carcinoma'. Together they form a unique fingerprint.

Cite this